- Trials with a EudraCT protocol (101)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
101 result(s) found for: Microenvironment.
Displaying page 1 of 6.
EudraCT Number: 2022-002599-35 | Sponsor Protocol Number: 2022-1-58-002 | Start Date*: 2022-10-21 | |||||||||||
Sponsor Name:Centre de Lutte Contre le Cancer Eugène Marquis | |||||||||||||
Full Title: Contribution of [18F]DPA-714 PET for grading and exploration of the inflammatory microenvironment of glioma, a pilot study. | |||||||||||||
Medical condition: glioma (grade OMS II à IV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004567-11 | Sponsor Protocol Number: 75911 | Start Date*: 2020-12-08 | |||||||||||
Sponsor Name:Zealand University Hospital | |||||||||||||
Full Title: Effect of Low-dose Interferon-alfa2a on peri operative immune suppression | |||||||||||||
Medical condition: pMMR Colon cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004130-15 | Sponsor Protocol Number: CRC-AGA-M-A-11 | Start Date*: 2014-06-03 | |||||||||||
Sponsor Name:Charité-Universitätsmedizin Berlin, Department of Dermatology, Clinical Research Center for Hair and Skin Science | |||||||||||||
Full Title: Investigator-initiated clinical research trial on the effects of 5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia | |||||||||||||
Medical condition: Androgenetic Alopecia Hamilton-Norwood IIIv-IV male patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004485-21 | Sponsor Protocol Number: HE9A/14 | Start Date*: 2015-04-03 | |||||||||||
Sponsor Name:Hellenic Cooperative Oncology Group | |||||||||||||
Full Title: A study of cabazitaxel treatment in castration resistant bone metastatic prostate cancer patients evaluating the tumor microenvironment | |||||||||||||
Medical condition: Castration resistant bone metastatic prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001843-37 | Sponsor Protocol Number: 52649 | Start Date*: 2019-08-06 | ||||||||||||||||||||||||||
Sponsor Name:Radboud University Medical Center | ||||||||||||||||||||||||||||
Full Title: Imaging of tumour microenvironment in patients with oropharyngeal head and neck squamous cell carcinoma using RGD PET/CT imaging. | ||||||||||||||||||||||||||||
Medical condition: The aim of this study is to assess differences in tumour microenvironment between HPV positive and HPV negative oropharyngeal head and neck squamous cell carcinoma using [68Ga]Ga-RGD2 PET/CT and p... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003778-29 | Sponsor Protocol Number: CIFRA | Start Date*: 2019-03-06 |
Sponsor Name:Istituto Nazionale Tumori G. Pascale | ||
Full Title: Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / V | ||
Medical condition: advanced colorectal carcinoma with wild type RAS and FcyRIIIA-V / V | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000177-37 | Sponsor Protocol Number: LITE | Start Date*: 2017-09-21 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Low-dose IL-2 to expand endogenous regulatory T cells and achieve tolerance in liver transplantation | |||||||||||||
Medical condition: Discontinuation of immunosuppression in liver transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003556-23 | Sponsor Protocol Number: PROMIT | Start Date*: 2019-10-15 | |||||||||||
Sponsor Name:University Hospital of the Friedrich-Alexander University Erlangen-Nürnberg | |||||||||||||
Full Title: A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA4 Blockade Pre... | |||||||||||||
Medical condition: Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022844-19 | Sponsor Protocol Number: | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU de Dijon | |||||||||||||
Full Title: Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma | |||||||||||||
Medical condition: Hodgkin Lymphoma not previously treated | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002904-15 | Sponsor Protocol Number: B9991011 | Start Date*: 2017-05-18 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIEN... | |||||||||||||
Medical condition: Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) SE (Completed) CZ (Prematurely Ended) GB (Completed) ES (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001181-38 | Sponsor Protocol Number: AuspiCiOus | Start Date*: 2021-07-29 |
Sponsor Name:Academic Medical Center | ||
Full Title: Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study | ||
Medical condition: Gastroesophageal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004606-60 | Sponsor Protocol Number: BP42772 | Start Date*: 2021-06-22 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS W... | |||||||||||||
Medical condition: Advanced or metastatic squamous cell carcinoma of the esophagus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Ongoing) DK (Ongoing) HU (Ongoing) BE (Ongoing) FR (Ongoing) IT (Ongoing) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000631-23 | Sponsor Protocol Number: BP43963 | Start Date*: 2022-11-03 | |||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY OF MULTIPLE DOSES OF RO7247669 IN PARTICIPANTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC MELANOMA | |||||||||||||
Medical condition: Unresectable or Metastatic Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) SK (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004071-34 | Sponsor Protocol Number: PRG-Opioid-06-/03 | Start Date*: 2009-01-14 |
Sponsor Name:Queen Mary, University of London (QMUL) | ||
Full Title: A single centre, parallel group, pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling. | ||
Medical condition: This study is not looking at any disease process | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-012350-20 | Sponsor Protocol Number: MSC-KTx | Start Date*: 2008-01-14 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: MESENCHYMAL STEM CELLS UNDER BASILIXIMAB/ LOW DOSE RATG TO INDUCE RENAL TRANSPLANT TOLERANCE | |||||||||||||
Medical condition: Patients will be those receiving a living-related kidney transplant | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003338-29 | Sponsor Protocol Number: MK-3475-100 | Start Date*: 2016-04-20 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer | |||||||||||||
Medical condition: A:platinum-resistant or partially platinum-sensitive recurrent ovarian cancer (OC) who received 1 but no more than 3 prior lines of anticancer regimens/local standard following primary or interval ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) ES (Completed) LT (Completed) DE (Completed) FI (Completed) NO (Completed) BE (Completed) NL (Completed) FR (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001165-24 | Sponsor Protocol Number: UC-0150/1704 | Start Date*: 2018-06-12 |
Sponsor Name:UNICANCER | ||
Full Title: A Multicentre, Randomised, Open-label, Phase 2 trial of mifamurtide combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnos... | ||
Medical condition: Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and s... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000894-11 | Sponsor Protocol Number: IRST153.04 | Start Date*: 2016-04-13 | ||||||||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS | ||||||||||||||||||
Full Title: Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II study | ||||||||||||||||||
Medical condition: colorectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004239-35 | Sponsor Protocol Number: 2017/16 | Start Date*: 2019-09-26 | |||||||||||
Sponsor Name:Centre Antoine Lacassagne | |||||||||||||
Full Title: Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas | |||||||||||||
Medical condition: Soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004552-15 | Sponsor Protocol Number: NANO-GBM | Start Date*: 2021-03-18 | |||||||||||
Sponsor Name:Centre Jean Perrin | |||||||||||||
Full Title: Phase I/II study of AGuIX nanoparticles with radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma | |||||||||||||
Medical condition: glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.